Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (491-500 of 627) with videos related to

Pageof 63
Sort By:
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Journal of Cardiovascular Computed Tomography|July 25, 2022
Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health StudyFrancois Haddad, Nicholas Cauwenberghs, Melissa A Daubert, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Journal of the American College of Cardiology|November 5, 2013
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention)Philippe Généreux, Gregg W Stone, Robert A Harrington, et al.
Clinical Cardiology|June 30, 2019
The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIXCelina M Yong, Vandana Sundaram, Freddy Abnousi, et al.
Journal of the American Heart Association|April 27, 2019
Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF RegistryAlexander C Perino, Peter Shrader, Mintu P Turakhia, et al.
American Heart Journal|April 30, 2017
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndromeConnie N Hess, Robert M Clare, Megan L Neely, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 63

Showing results (491-500 of 627) with videos related to

Sort By:
Pageof 63
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Journal of Cardiovascular Computed Tomography|July 25, 2022
Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health StudyFrancois Haddad, Nicholas Cauwenberghs, Melissa A Daubert, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Journal of the American College of Cardiology|November 5, 2013
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention)Philippe Généreux, Gregg W Stone, Robert A Harrington, et al.
Clinical Cardiology|June 30, 2019
The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIXCelina M Yong, Vandana Sundaram, Freddy Abnousi, et al.
Journal of the American Heart Association|April 27, 2019
Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF RegistryAlexander C Perino, Peter Shrader, Mintu P Turakhia, et al.
American Heart Journal|April 30, 2017
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndromeConnie N Hess, Robert M Clare, Megan L Neely, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 63